The LogicBio team is passionate, driven and fiercely committed to delivering on the promise of genetic medicine to transform the lives of children with rare genetic diseases. We recognize that our mission is best achieved by working together with the patient communities that we are focused on. By understanding the unmet needs of patients and the challenges faced in daily disease management, we are able to do our jobs with purpose. By listening and learning from advocates, patients, and caregivers, we can better understand how these diseases affect the lives of patients and their families. And by collaborating with advocacy organizations throughout the drug development process, we can achieve our shared goals more efficiently.
“Every day, patients and their families are on our minds driving a steadfast commitment to address their high unmet needs.”
Fred Chereau, President & CEO of LogicBio.
Our mission is to provide the first disease-modifying therapy for patients living with MMA. We selected MMA as the first indication for our gene-editing platform because of the clear unmet need that exists today.